CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2017.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
CARBON DIOXIDE, USP is an inhalation gas approved in 2017 with X-Ray contrast activity mechanism of action. It is used as a contrast agent for imaging procedures via inhalation route. This product represents a specialized diagnostic modality in the gas/inhalation space.
Peak lifecycle stage suggests stable commercial operations with established market presence, though modest linked job count indicates specialized, smaller team footprint.
X-Ray Contrast Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Martin Pharmaceuticals is hiring 1 role related to this product
CARBON DIOXIDE, USP shows zero linked job postings, reflecting a specialized, mature diagnostic product with limited hiring velocity. Career opportunities are concentrated in sustaining commercial operations, medical education, and regulatory compliance rather than growth-phase expansion.